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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of sedative, analgesic, and anaesthetic drugs on neurological outcomes in adults with moderate-to-severe TBI.
B A C K G R O U N D
Description of the condition
Traumatic brain injury (TBI) is a leading cause of morbidity and
mortalityworldwide (CDC 2014). Trauma to the brain is classified
as primary or secondary, and both types of injury can occur simul-
taneously as a continuum of overlapping neurological insults. Pri-
mary injury occurs with the initial trauma and can result in diffuse
or localised injury, cerebral oedema, and intracranial haemorrhage,
any of which can raise intracranial pressure (ICP), reduce cere-
bral perfusion pressure (CPP), or worsen cerebral ischaemia. Sec-
ondary injury occurs as a result of additional neurological insults
from hypercapnoea, hypoxia, systemic hypotension, and raised
ICP. Both primary and secondary brain injuries are associated with
increased mortality, as well as long-term neurological morbidity
(e.g. impairments in memory and reasoning, as well as behavioural
and mental health disorders) (Brain Trauma Foundation 2007;
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Chowdhury 2014; Ribbers 2010; Roberts 2011).
Description of the intervention
Sedatives and opioids are commonly used in the intensive care
unit (ICU) to facilitate the use of life-supporting technologies (e.g.
support ventilator synchrony), mitigate pain, and reduce anxi-
ety and agitation (Arroliga 2005; Barr 2013; Burry 2014). While
these drugs facilitate tolerance of the ICU environment, there are
notable complications associated with their use. Careful selection
of drug(s) and method of titration are endorsed by the Society
of Critical Care Medicine given the accumulating data indicating
suboptimal sedation practices may prolong mechanical ventila-
tion, and increase delirium and long-term cognitive impairment
(Arabi 2007; Barr 2013; Brattebo 2004; Brook 1999;Girard 2008;
Kollef 1998; Kress 2000; Kress 2003; Pandharipande 2007; Strøm
2010). In addition to the traditional application of sedation in the
ICU, drugs may be administered in people with TBI, especially in
the acute phase following the initial injury. Sedatives and opioids,
as well as anaesthetics, are often used in the TBI population to
control ICP, reduce metabolic rate (e.g. cerebral metabolic rate of
oxygen (CMRO2)), manage or prevent seizures, and improve me-
chanical ventilator synchrony to achieve optimal arterial blood gas
(partial pressure of carbon dioxide in arterial blood (PaCO2) and
partial pressure of oxygen in arterial blood (PaO2)) concentrations
(Brain Trauma Foundation 2017; Kelly 1999; Skoglund 2013).
Unfortunately, many of these drugs are associated with adverse
effects (e.g. haemodynamic instability) that may consequently in-
crease the risk of secondary brain injury (Roberts 2012; Urwin
2004). In addition, the long-term effects of these agents on cog-
nitive outcomes are unknown. An ideal sedative for people with
acute severe TBI would: 1. confer neuroprotection (e.g. ICP con-
trol and reduction in CMRO2) without compromising systemic
haemodynamics or causing adverse effects (e.g. propofol infusion
syndrome); 2. permit frequent neurological assessment; 3. address
specific symptoms of agitation, anxiety, ventilator dyssynchrony,
and pain; and 4. improve clinical outcomes (e.g. neurological func-
tion, duration of mechanical ventilation, and survival) (Barr 2013;
Brain Trauma Foundation 2007; Chowdhury 2014; Flower 2012;
Urwin 2004).
How the intervention might work
Various sedative, opioid, and anaesthetic agents are used in the
acute management of moderate-to-severe TBI. These drugs can
be used in the traditional context of sedation and analgesia, but
can also be employed for their neuroprotective properties (e.g.
reduction of cerebral metabolic rate and oxygen consumption).
Sedatives, opioids, and anaesthetics may, therefore, play a role in
the optimisations of patient care, improving both short- and long-
term (e.g. neurological function) outcomes. Unfortunately, the
majority of these drugs can also cause important adverse effects
(e.g. systemic hypotension, bradycardia) especially when adminis-
tered at higher doses to achieve deep sedation. Propofol, benzodi-
azepines, and barbiturates are thought to act as neuroprotectants
through their modulation of gabaminergic transmission, where
they reduce cerebral blood flow (CBF), CMRO2, and ICP (Urwin
2004). The alpha2−adrenergic agonist dexmedetomidine reduces
CBF and ICP, and ketamine is an antagonist of N-methyl-D-as-
partate (NMDA) receptors, where it decreases cerebral glutamate
activity. Lastly, opioidsmodulate themu receptor where they affect
pain, but they can also be used for their sedating properties. Many
of the aforementioned drugs confer broad therapeutic effects. For
example, ketamine can be used for analgesia, and propofol, ben-
zodiazepines, and barbiturates have anticonvulsant properties.
Why it is important to do this review
The World Health Organization (WHO) has predicted TBI will
surpassmany illnesses, including cancer and cardiovascular disease,
as the major cause of death and disability by 2020 (Mathers
2006). In the US, more than 1.4 million people experience a TBI
each year, with 50,000 reported deaths (Richmond 2011). The
economic burden of TBI is considerable: in the US, the estimated
combined direct and indirect economic cost of TBI in 2010 was
estimated at USD 76.5 billion (CDC 2014).
The Society of Critical Care Medicine 2013 Pain, Agitation and
DeliriumGuidelines recommend a light level of sedation using ei-
ther protocolised sedation or daily sedation interruption in adults
in the ICU, as this is associated with improved clinical outcomes
(Barr 2013). However, these guidelines do not provide direction
on general sedation practice for people with moderate-to-severe
TBI. The Brain Trauma Foundation guidelines for management
of severe TBI suggest high-dose barbiturates may be necessary to
control elevated ICP refractory to standard drug or surgical inter-
ventions while ensuring haemodynamic stability (Brain Trauma
Foundation 2017). The guidelines also caution against the use of
high-dose propofol for ICP management given the associated ad-
verse events (e.g. metabolic acidosis, rhabdomyolysis) and mor-
bidity.
In addition to the overall sparsity of resources to guide the clinical
management of moderate-to-severe TBI, an important limitation
of existing reviews and guidelines is that interventionswere consid-
ered in isolation and only direct evidence from head-to-head com-
parisons (i.e. employing pair-wise meta-analytic techniques) was
used (Brain Trauma Foundation 2017; Gu 2014; Roberts 2011;
Roberts 2012). Given this limitation, we propose a novel synthesis
of the evidence using a network meta-analysis (NMA), a power-
ful statistical approach that enables the inclusion of both direct
and indirect evidence in a multi-treatment analytical framework
(Catala-Lopez 2014; Ioannidis 2009; Lu 2004).
An NMA framework will enable the determination of the rela-
tive efficacy and safety of sedative, analgesic, and anaesthetic drugs
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that may not have been previously compared head-to-head in pub-
lished trials or reviews. This is particularly important given the
growing use of new sedative agents (e.g. dexmedetomidine) in the
TBI population (Tang 2011; Wang 2013). The findings of this
NMA will highlight the comparative benefits and harms of each
intervention and permit their ranking according to effectiveness
and acceptability. An updated knowledge synthesis in this area will
inform treatment algorithms and provide guidance to clinicians,
ultimately guiding future research protocols and knowledge trans-
lation opportunities.
O B J E C T I V E S
To assess the effects of sedative, analgesic, and anaesthetic drugs
on neurological outcomes in adults with moderate-to-severe TBI.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs), including
those of open-label design. We will exclude crossover studies and
studies examining the effects of sedatives for procedural purposes
specifically (e.g. intubation). We will also exclude studies of pre-
hospital care of people with TBI. We will only include trials that
were prospectively registered, unless the final report was published
before 2010.
Types of participants
We will include studies that enrol adults aged over 16 years diag-
nosed with moderate-to-severe TBI.
Types of interventions
We will include studies comparing any sedative, analgesic, or
anaesthetic to an alternative drug of either the same or different
class, or to placebo, for the management of moderate-to-severe
TBI. Interventions will include alpha-2-agonists (e.g. dexmedeto-
midine), anaesthetics (e.g. volatile gases), benzodiazepines (e.g.
midazolam), non-benzodiazepine sedatives (e.g. propofol), barbi-
turates (e.g. pentobarbital), and opioids (e.g. fentanyl). For this
analysis, drug dose, duration of use, and route of administration
will not be restricted. Each drug class will have an individual node
in the NMA framework. Additional interventions identified in
the search will be considered in the framework if the study meets
prespecified inclusion criteria.
Types of outcome measures
Primary outcomes
1. Neurological outcome (Glasgow Outcome Scale (GOS) or
the Glasgow Outcome Scale Extended (GOSe), measured at
three and six months).
Secondary outcomes
1. Cerebral haemodynamic measures (i.e. ICP, CPP) in the
acute phase (i.e. 24 to 72 hours, related to the primary TBI
injury and the main reason for administering sedation).
2. Cerebral oxygenation (CMRO2) in the acute phase (i.e. 24
to 72 hours).
3. Duration of mechanical ventilation (days).
4. ICU and hospital length of stay (days).
5. Mortality (e.g. one, three, six, or 12 months, or as reported
by study authors).
6. Adverse events (e.g. hypotension, bradycardia).
Search methods for identification of studies
To reduce publication and retrieval bias, we will not restrict studies
based on language, date, or status of publication.
Electronic searches
The Cochrane Injuries Group Information Specialist will search
the following:
1. Cochrane Injuries Group specialised register (present
version);
2. the Cochrane Library (www.cochranelibrary.com/) (latest
issue);
3. Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid OLDMEDLINE(R) (1946 to present);
4. Embase Classic + Embase (OvidSP) (1947 to present);
5. PubMed (www.ncbi.nlm.nih.gov/pubmed/) (present);
6. ISI Web of Science: Science Citation Index Expanded (SCI-
EXPANDED) (1970 to present);
7. ISI Web of Science: Conference Proceedings Citation
Index-Science (CPCI-S) (1990 to present);
8. LILACS (lilacs.bvsalud.org/) (present);
9. PROSPERO (www.crd.york.ac.uk/prospero/search.asp)
(present);
10. Clinicaltrials.gov (www.clinicaltrials.gov);
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11. WHO International Clinical Trials Registry Platform (
apps.who.int/trialsearch/).
We will adapt the MEDLINE strategy (Appendix 1) as necessary
for other databases.
We will use the search filters and a modified version of the
“Cochrane Highly Sensitive Search Strategies” for identifying
RCTs in MEDLINE and Embase (Lefebvre 2011).
Searching other resources
We will perform a search of grey literature databases and websites
using resources listed in CADTH’s Grey Matters (www.cadth.ca/
en/resources/finding-evidence-is/grey-matters).
We will handsearch the abstracts from the annual scientific meet-
ings of relevant groups (e.g. Society of Critical Care Medicine,
World Congress on Brain Injury, Neurocritical Care Society, Eu-
ropean Society of Intensive Care Medicine) from the five years
prior to the review’s search date.
We will also search for unpublished and ongoing trials at
www.who.int/trialsearch and ClinicalTrials.gov using the term
“traumatic brain injury.”
We will handsearch the reference lists of all screened and included
studies, as well as any reviews published in the five years prior to
the review’s search date focusing on sedation in people with TBI
for identification of potential additional studies.
Data collection and analysis
Selection of studies
Two authors (LD, LB) will develop and pilot the study screening
form (Appendix 2) on five studies to ensure its ability to accurately
identify studies meeting inclusion criteria. Two authors (LD, LB)
will use the study screening form to independently examine each
title and abstract generated through the searches to identify eligible
studies. We will refer any disagreements to a third independent
author (AT), if needed. We will organize references in EndNote (
EndNote 2014). This systematic reviewwill adhere to best practice
reporting guidelines using the PRISMA criteria (Moher 2009).
A PRISMA-compliant flow diagram will demonstrate the search
and study selection process.
Data extraction and management
We will perform data extraction using a standardized electronic
form developed by two authors (LD, LB) and piloted on three
studies to ensure its ability to capture all relevant data. Pairs of au-
thors (LR and DW; SM and EG; ND and NA) will independently
extract the data using the standardized data extraction form.
We will extract data related to the following:
1. study design;
2. publication year and authors;
3. trial population (e.g. sample size, age, percentages of people
with moderate and severe TBI in the sample);
4. interventions (i.e. sedative agent used, dose, duration of
use, route of administration);
5. control or comparators;
6. selected outcomes.
We will also extract data on randomisation methods, allocation
concealment, blinding, frequency and handling of missing data,
adherence to intention-to-treat, and selective reporting of out-
comes (Higgins 2011). Given our familiarity with the literature,
we will not blind data extractors to the authors of included studies.
All data extraction will be checked for accuracy, and any discrep-
ancies will be resolved by an independent author (LD).
We are aware that all outcomes may not be reported in each trial.
Whenever possible, if outcomes of interest have been omitted,
we will attempt to contact the corresponding author(s) of eligible
trials to obtain additional information. In the event that abstracts
are identified that present relevant data, we will also endeavour to
contact study authors directly for additional study details.
Assessment of risk of bias in included studies
Two authors (LR and DW; SM and EG; ND and NA) will in-
dependently assess risk of bias of included studies. Assessment of
bias will be compared between authors, and one author (SM) will
resolve discrepancies, if necessary.
These assessments will use a domain-based evaluation embedded
in the data extraction form. We will use the Cochrane tool frame-
work for assessing bias and include the following domains (Higgins
2011):
1. random sequence generation (i.e. selection bias);
2. allocation concealment (i.e. selection bias);
3. blinding of participants and personnel (i.e. performance
bias);
4. blinding of outcomes assessment (i.e. detection bias);
5. incomplete outcome data (i.e. attrition bias);
6. selective reporting; and
7. other bias.
For each domain, we will assess the risk of bias as ’low,’ ’high,’
or ’unclear’ risk. An ’unclear’ assessment will be assigned if insuf-
ficient information is reported, or if the risk of bias is unknown
despite attempts to contact a study author. Once the risk of bias is
agreed upon, each study will be assigned to one of the following
categories:
1. low risk of bias: describes studies where all domains are
deemed to have ’low’ risk of bias;
2. high risk of bias: describes studies where one or more
domains are scored as ’no’ indicating ’high’ risk of bias; or
3. unclear risk of bias: describes studies where one or more
domain was scored as ’unclear’ risk or one domain was scored as
’high’ risk of bias.
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We will generate a risk of bias summary figure upon completion
of these assessments.
Measures of treatment effect
For cerebral outcomes, we will meta-analyse between-group dif-
ferences in the acute phase (i.e. 24 to 72 hours) (this acute period
finding will be reported in the ’Summary of findings’ table) if there
are sufficient data for pooling. We will analyse functional out-
come measure (e.g. GOS and GOSe) in a dichotomous manner.
Favourable outcome measures will be defined as a GOS of 1 to 3
or a GOSe of 1 to 5, while unfavourable outcomes will be defined
as a GOS of 4 or 5 or a GOSe of 6 to 8. Dichotomous outcomes
will be expressed as risk ratios with 95% confidence intervals.
Risk ratio was selected over risk difference to measure the effects
of binary outcomes due its superior consistency across a range of
baseline risks (Deeks 2002). Continuous variables (e.g. length of
ICU stay, duration of mechanical ventilation, ICP, CPP) will be
assessed using a mean difference and odds ratios. If the data are
skewed, these will be log transformed. We will consider two-sided
P ≤ 0.05 to be statistically significant.
Unit of analysis issues
We will use individual study participants in each trial arm as the
unit of analysis.
Dealing with missing data
We will contact the study authors to request missing or additional
data, or for clarification on how missing data were dealt with in a
particular study.
Assessment of heterogeneity
If assessed outcomes lack data, or if studies are too clinically or
methodologically (or both) heterogeneous to permit pooling of
data, we will report data in a table format and summarize them
qualitatively.
Where appropriate, wewill assess for statistical heterogeneity using
Chi2 and I2 tests. The Chi2 test assesses whether the observed
differences in results are compatible with chance alone. A low P
value provides evidence of heterogeneity of intervention effects
that is beyond chance (P < 0.10will be significant) (Higgins 2003).
Assessment of the I2 statistic describes the percentage of variability
in effect estimates that is due to data heterogeneity rather than
chance (i.e. sampling error) (Higgins 2011). Studies also will be
assessed for types and sources of heterogeneity, either clinical or
methodological, when making the decision to pool data. Clinical
heterogeneity will be assessed through examination of the type and
dose of sedative, and use of rescue sedation. We will also assess for
heterogeneity by performing analyses based on potential modifiers
of treatment effect, including the severity of TBI and year of study
publication.
Assessment of reporting biases
Reporting biases can occur due to an increased likelihood of pos-
itive trials (large or small) being published compared to negative
trials. For comparisons where at least 10 studies are available, we
will construct funnel plots in Review Manager 5 (RevMan 2014)
to assess for possible publication bias (Egger 2007; Higgins 2011).
Data synthesis
Wewill conduct pair-wisemeta-analyses for all outcomes and com-
parisons where three or more studies are available, using a ran-
dom-effects model with the Der Simonian and Laird method. A
random-effects model employs a more conservative approach than
a fixed-effect model, as it considers the variability within a study
as well as among studies (Higgins 2011).
We will perform NMA within a Bayesian framework by assum-
ing a common heterogeneity parameter across all comparisons.
We will perform analyses usingWinBUGS software (version 1.4.3
MRC Biostatistics Unit, Cambridge, UK) through well-estab-
lishedmethods (Lu 2006; Salanti 2011).We will adhere to the rec-
ommendations from the PRISMA-NMA for reporting identified
findings including forest plots, and rank-o-grams (Hutton 2015).
Subgroup analysis and investigation of heterogeneity
We will perform the following subgroup analyses:
1. severity of TBI: (moderate (i.e. Glasgow Coma Score
(GCS) 9 to 12) versus severe (i.e. GCS 3 to 8)).
2. indication for sedation (i.e. presence or absence of ICP).
Sensitivity analysis
We will perform a sensitivity analysis removing studies rated as
high risk of bias. We will use trial sequential analysis methods to
explore any statistically significant effect found where the outcome
did not meet the expected sample size.
Presentation of main results
We will present each comparison and selected outcomes of the
review using a ’Summary of findings’ table (Schunëmann 2011a),
including the following outcomes
1. neurological outcome as measured by GOS/GOSe (at three
and six months);
2. ICP;
3. CPP;
4. duration of mechanical ventilation;
5. hypotension.
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The ’Summary of findings’ table will include an overall grad-
ing of the evidence using the principles of the GRADE system
(tech.cochrane.org/revman/gradepro; Schunëmann 2011b). We
will grade the quality of evidence for our selected outcomes as
high, moderate, low, or very low, based on risk of bias, within
study evidence directness, heterogeneity, precision of effect esti-
mates, and publication bias. We will base the control event rates
for the calculation of absolute risks on the number of events in the
included studies.
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A P P E N D I C E S
Appendix 1. Search strategy
Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid
OLDMEDLINE(R) (1946 to present)
1. exp Craniocerebral Trauma/ or exp Cerebrovascular Trauma/
2. (TBI or mTBI or sTBI or ((trauma* or mild* or moderate* or severe* or acquired) and (brain injur* or brain trauma* or head injur*
or head trauma*))).ti,ab,kf.
3. *Multiple Trauma/
4. Glasgow Coma Scale/ or Glasgow Outcome Scale/
5. (Glasgow adj (coma or outcome) adj (scale* or score*)).ab,ti,kf.
6. (injur* or trauma* or damag* or wound* or fractur* or contusion* or haematoma* or hematoma* or haemorrhag* or hemorrhag* or
pressur* or hypertensi* or lesion* or destruction* or oedema* or edema* or contusion* or concus*).ti,ab,kf.
7. (4 or 5) and 6
8. ((mild* or moderate* or severe*) adj5 (unconscious* or coma* or concuss*) adj3 (injur* or trauma* or damag* or wound* or fracture*
or contusion* or haematoma* or hematoma* or haemorrhag* or hemorrhag* or pressur* or hypertensi*)).ti,ab,kf.
9. ((mild* or moderate* or severe*) adj5 (head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra
cran* or inter cran* or intracran* or intercran*) adj3 (injur* or trauma* or damag* or lesion* or wound* or destruction* or oedema*
or edema* or contusion* or concus* or fracture* or pressure or hypertensi*)).ab,ti,kf.
10. (neurprotect* and ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra cran* or inter cran* or
intracran* or intercran*) adj3 (injur* or trauma* or damag* or lesion* or wound* or destruction* or oedema* or edema* or contusion*
or concus* or fracture* or pressure or hypertension))).ab,ti,kf.
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11. (subarachnoid h?emorrhage or tSAH).ti,ab,kf.
12. ((midbrain or mid brain) adj syndrome).ti,ab,kf.
13. diffuse axonal injur*.ti,ab,kf.
14. (or/1-3,7,8-13)
15. Conscious Sedation/
16. (sedative* or sedation).ti,ab,kf.
17. exp Adrenergic alpha-2 Receptor Agonists/
18. (Brimonidine or Clonidine or Dexmedetomidine or MPV-1440 or Guanabenz or Guanfacine or Medetomidine or Methyldopa
or Xylazine).ti,ab,kf,rn.
19. exp “Hypnotics and Sedatives”/
20. (Propofol or Lidocaine or Tetracaine or Etomidate).ti,ab,kf,rn,sh.
21. (Ketamin* or Amantadin* or Atomoxetin* or Dextromethorphan or GLYX 13 or “MK 0657” or Lanicemin* or AZD6765 or
Memantin* or Quinolin or Rellidep or Riluzol or Tramadol or ETS6103 or NMethyl D Aspartate or NMDA or NRX 1074 or Kainite
or Gavestinel or GV150526).ti,ab,kf,rn,sh.
22. (Barbiturat* or Amobarbital or Barbital or Hexobarbital or Mephobarbital or Methohexital or Murexide or Pentobarbital or
Phenobarbital or Primidone or Secobarbital or Thiobarbiturate* or Thiamylal or Thiopental or Thiopentobarbital* or Thiopentone
or Penthiobarbital ).ti,ab,kf,rn,sh.
23. (Benzodiazepin* or BZD or Abecarnil or Adinazolam or Alprazolam or Arfendazam or Bentazepam or Bretazenil or Bromazepam
or Brotizolam or Camazepam or Chlordiazepoxide or Chlordesmethyldiazepam or Cinolazepam or Clobazam or Clonazepam or
Clorazepate or Chlorazepate or Clotiazepam or Cloxazolam or Delorazepam or Demoxepam or Desmethyldiazepam or Desoxyde-
moxepam or Devazepide or Diazepam or Doxefazepam or Estazolam or ethyl loflazepate or CM 6912 or Etizolam or Fludiazepam
or Flunitrazepam or Flurazepam or dealkylflurazepam or Flutoprazepam or Fosazepam or Gidazepam or Girisopam or Halazepam
or Haloxazolam or Ketazolam or Loflazepate or Loprazolam or Lorazepam or Lormetazepam or Meclonazepam or Medazepam or
Metaclazepam or Mexazolam or Midazolam or Nerisopam or Nimetazepam or Nitrazepam or Norchlordiazepoxide or Norclobazam
or Nordazepam or Norfludiazepam or Norflunitrazepam or Oxazepam or WY 3498 or Oxazolam or Phenazepam or Pinazepam or
Prazepam or Premazepam or Propazepam or Quazepam or Ripazepam or Serazepine or Sograzepide or Talampanel or Tarazepide or
Temazepam or Tetrazepam or Tofisopam or Triazolam or Zolazepam or Zaleplon or Zolpidem or Zopiclone or Eszopiclone or Z
Drug*).ti,ab,kf,rn,sh.
24. (Azaperone or Bromisovalum or Chloral hydrate or Chloralose or Chlormethiazole or Diphenhydramine or Ethchlorvynol or
Etomidate or Etorphine or Glutethimide or Medetomidine or Meprobamate or Methapyrilene or Methaqualone or Paraldehyde or
Xylazine).ti,ab,kf,rn,sh.
25. exp Narcotics/
26. exp Analgesics, Opioid/
27. (Alfentanil or Fentanyl or Remifentan* or Sufentanil or Hydromorphone or Dihydromorphinone or Morphine or Opiate* or
Opioid*).ti,ab,kf,rn,sh.
28. or/15-27
29. randomi?ed.ab,ti.
30. randomized controlled trial.pt.
31. controlled clinical trial.pt.
32. placebo.ab.
33. clinical trials as topic.sh.
34. randomly.ab.
35. trial.ti.
36. Comparative Study/
37. or/29-36
38. (animals not (humans and animals)).sh.
39. 37 not 38
40. (14 and 28 and 39)
9Sedation for moderate-to-severe traumatic brain injury in adults: a network meta-analysis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 2. Study screening form
Review author Initials Review date: / / (dd/mm/yy)
Primary author
Citation (title, journal, year, vol, pg)
Level of review Title and abstract Full text
STUDY SELECTION STUDY SELECTION
Study type RCT or non-randomized study Yes No
Population Majority (≥ 50%) of study participants are≥ 16 years old with moderate-
to-severe TBI (GCS = 3-12 or documented traumatic head/brain injury)
Yes No
Study participants received care in an intensive care setting (critical care or
intensive care of any specialty)
Yes No
Intervention Pharmacological sedation Yes No
Study does not use intervention exclusively or rapid-sequence intubation Yes No
Compar-
ison (only for
RCTs)
Alternative pharmacological sedation or placebo Yes No
Decision INCLUDE EXCLUDE
Primary reason for exclusion Study type
Population Population
Intervention Intervention
Comparison Comparison
GCS: Glasgow Coma Score; RCT: randomized controlled trial; TBI: traumatic brain injury GCS: Glasgow Coma
controlled trial; TBI:
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C O N T R I B U T I O N S O F A U T H O R S
Drafting of protocol: LB; LD; LR; DW; NA; AT; EG; ND; DF; BH; and SM.
D E C L A R A T I O N S O F I N T E R E S T
LB: none known.
LD: none known.
LR: none known.
DW: has received an educational research grant from Hospira (now Pfizer), the company that makes Precedex (dexmedetomidine).
NA: none known.
AT: none known.
EG: none known.
ND: none known.
DF: none known.
BH: none known.
SM: none known.
S O U R C E S O F S U P P O R T
Internal sources
• None, Other.
External sources
• No sources of support supplied
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